About Us

Global Kinetics

Global Kinetics

About Us

Global Kinetics Pty Ltd. is committed to improving the lives of those with Parkinson’s disease with advanced medical technologies. The company was formed in 2007 to commercialize its lead product, the Personal KinetiGraph® (PKG®). The PKG enables the precise monitoring, quantification, and reporting of movement symptoms in Parkinson’s disease. To date, Global Kinetics has supported clinical decisions for doctors who have treated more than 30,000 patients with Parkinson’s disease, generating more than 7 million hours of clinical data from the FDA-cleared, CE-marked, TGA-cleared PKG wearable system. Global Kinetics is a privately held company, headquartered in Melbourne, Australia with offices in London and Minneapolis.

Company Overview

Global Kinetics

Global Kinetics Pty Ltd (GK), a novel digital health company, is revolutionising the management of Parkinson’s disease by providing the first continuous and objective measurement of patients’ symptoms in everyday environments.

The PKG System

History of the PKG system

Initial development of the technology behind the PKG® system began in the late 1990s by Professor Malcolm Horne and Dr Rob Griffiths at the world-renowned Florey Institute of Neuroscience and Mental Health in Melbourne, Australia. The pair worked on developing the data logger, assessment and report creation technology and in 2007, Global Kinetics Corporation (GKC) was established to commercialise this innovative technology.

The PKG® system has evolved to include advanced monitoring technology and reporting capabilities and in 2016 the next generation data logger featuring an interactive touch-screen design – the PKG Watch was launched.

Key milestones for the PKG® system:

loading
  • 2007

    2007

    2007

    January 1, 2007
    • Global Kinetics Corporation Ltd Established
  • 2009

    2009

    2009

    January 1, 2009
    • 1st external funding
  • 2011

    2011

    2011

    January 1, 2011
    • Series 2 capital raise
    • Initial product development
    • POC clinical studies underway
  • 2012

    2012

    2012

    January 8, 2012
    • TGA Registration
    • CE Mark
    • 1st product in Australia
    • 1st product in Europe
    • 1st publication
  • 2014

    2014

    2014

    January 1, 2014
    • Series 3 Capital raise
    • 53 Clinical sites
    • 1st patent granted
    • US Market launch
  • 2015

    2015

    2015

    January 1, 2015
    • Series 4 Capital raise
    • US FDA Clearance
    • CE Mark 11a
    • 1st Reimbursement Sweden
  • 2016

    2016

    2016

    January 1, 2016
    • Series 5 Capital raise
    • Second Generation device receives FDA clearance
  • 2017

    2017

    2017

    January 1, 2017
    • +3 million PKG recording hrs
    • Second Generation device receives CE mark
    • 1st US patent granted
    • Fast Company Top 10 in Health
  • 2018

    2018

    2018

    January 1, 2018
    • Series 6 Capital raise
    • Roll down: creation of Global Kinetics Pty Ltd and assignment of all asset and liabilities for shares
  • 2019

    2019

    2019

    January 1, 2019
    • Continuous Monitoring product launched
    • Clinical Trial Services business launched
  • 2020

    2020

    2020

    January 1, 2020
    • +50 million PKG recording hrs
    • 23 peer-reviewed studies
    • RPM Pilot
  • 2021

    2021

    2021

    September 8, 2021
    • RPM Launched in the US
    • 60,000 PKGs recorded

Interested in learning more about PKG?